Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.
Human papillomavirus (HPV)-induced lesions are distinct in that they have targetable foreign antigens, the expression of which is necessary to maintain the cancerous phenotype. Hence, they pose as a very attractive target for "proof of concept" studies in the development of therapeutic vaccines. This review will focus on the most recent clinical trials for the immunotherapy of mucosal and cutaneous HPV-induced lesions as well as emerging therapeutic strategies that have been tested in preclinical models for HPV-induced lesions. Progress in peptide-based vaccines, DNA-based vaccines, viral/bacterial vector-based vaccines, immune response modifiers, photodynamic therapy and T cell receptor based therapy for HPV will be discussed.
Kanodia
Shreya
S
Department of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.
Da Silva
Diane M
DM
Kast
W Martin
WM
D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D027383:Papillomaviridae / Q000378:metabolism*; D030361:Papillomavirus Infections / Q000276:immunology* / Q000628:therapy*; D053918:Papillomavirus Vaccines; D010641:Phenotype; D010778:Photochemotherapy / Q000379:methods; D019444:Vaccines, DNA
D053918:Papillomavirus Vaccines; D019444:Vaccines, DNA